Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

NCT05009732 is registered in ClinicalTrials.gov with Suzhou Kintor Pharmaceutical Inc, as lead sponsor.

NCT NCT05009732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05009732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2021
Completion date
July 14, 2023
Enrollment
139 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

covid19